An innovative approach to overcoming PD-1 resistance: Combined TIGIT blockade with nanophotothermal therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Photodynamic and photothermal therapies: synergy opportunities for nanomedicine10.1021/acsnano.3c00891 ↗
2. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods10.1021/ja057254a ↗
3. Second near-infrared light-activatable polymeric nanoantagonist for photothermal immunometabolic cancer therapy
4. Near infrared photothermal conversion materials: mechanism, preparation, and photothermal cancer therapy applications10.1039/D1TB01310F ↗
5. Mitochondria-associated ER stress evokes immunogenic cell death through the ROS-PERK-eIF2alpha pathway under PTT/CDT combined therapy10.1016/j.actbio.2023.02.011 ↗
6. How did conventional nanoparticle-mediated photothermal therapy become "hot" in combination with cancer immunotherapy?10.3390/cancers14082044 ↗
7. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future10.1136/jitc-2020-001926 ↗
8. Targeting immunogenic cell death in cancer10.1002/1878-0261.12851 ↗
9. CD4(+) T cell help in cancer immunology and immunotherapy10.1038/s41577-018-0044-0 ↗
10. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency
11. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death10.1038/s41467-019-11269-8 ↗
12. The dendritic cell system and its role in immunogenicity10.1146/annurev.iy.09.040191.001415 ↗
13. The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules10.1146/annurev-immunol-041015-055254 ↗
14. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells10.1038/sj.cgt.7700509 ↗
15. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes10.1038/nature01441 ↗
16. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer10.1126/sciadv.abe3348 ↗
17. Dual roles of immune cells and their factors in cancer development and progression10.7150/ijbs.7.651 ↗
18. Systemic immunity is required for effective cancer immunotherapy10.1016/j.cell.2016.12.022 ↗
19. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination10.1146/annurev.immunol.20.100301.064812 ↗
20. New aspects of natural-killer-cell surveillance and therapy of cancer10.1038/nrc928 ↗
21. Perforin dependence of natural killer cell-mediated tumor control in vivo10.1002/eji.1830251246 ↗
22. Granzymes in cancer and immunity10.1038/cdd.2009.206 ↗
23. Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells10.1007/s002620100191 ↗
24. Progress in tumor-associated macrophage (TAM)-targeted therapeutics10.1016/j.addr.2017.04.010 ↗
25. The multifaceted role of perivascular macrophages in tumors10.1016/j.ccell.2016.05.017 ↗
26. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment10.3389/fphar.2022.868695 ↗
27. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors10.1016/j.cmet.2017.06.004 ↗
28. The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses10.3389/fimmu.2020.00940 ↗
29. Immune surveillance of tumors10.1172/JCI31405 ↗
30. The combination of eddy thermal effect of biodegradable magnesium with immune checkpoint blockade shows enhanced efficacy against osteosarcoma
31. Engineering Au(44) nanoclusters for NIR-II luminescence imaging-guided photoactivatable cancer immunotherapy10.1021/acsnano.3c02370 ↗
32. Multifunctional light-activatable nanocomplex conducting temperate-heat photothermal therapy to avert excessive inflammation and trigger augmented immunotherapy10.1016/j.biomaterials.2022.121815 ↗
33. Improvement of TNBC immune checkpoint blockade with a microwave-controlled ozone release nanosystem10.1016/j.jconrel.2022.09.053 ↗
34. A mild hyperthermia hollow carbon nanozyme as pyroptosis inducer for boosted antitumor immunity10.1021/acsnano.3c07601 ↗
35. An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer
36. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade10.1073/pnas.192461099 ↗
37. T cell exhaustion10.1038/ni.2035 ↗
38. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression10.1016/j.semcancer.2005.07.005 ↗
39. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells10.1038/ni.1674 ↗
40. Targeting TIGIT for cancer immunotherapy: recent advances and future directions10.1186/s40364-023-00543-z ↗
41. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
42. pH-sensitive and bubble-generating mesoporous silica-based nanoparticles for enhanced tumor combination therapy10.1016/j.apsb.2020.08.013 ↗
43. Polydopamine-mesoporous silica core-shell nanoparticles for combined photothermal immunotherapy10.1021/acsami.0c10781 ↗
44. Surface-engineered vanadium nitride nanosheets for an imaging-guided photothermal/photodynamic platform of cancer treatment10.1039/C8NR08269C ↗
45. Laser-induced breakdown spectroscopy-guided synergistic phototherapy: a theranostic platform mediated by a single laser wavelength10.1016/j.colsurfb.2022.112768 ↗
46. Immunogenic cell death in cancer: concept and therapeutic implications10.1186/s12967-023-04017-6 ↗
47. In situ nanofiber patch boosts postoperative hepatocellular carcinoma immune activation by trimodal combination therapy10.1021/acsnano.3c05829 ↗
48. A guide to cancer immunotherapy: from T cell basic science to clinical practice10.1038/s41577-020-0306-5 ↗
49. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer10.1080/2162402X.2016.1249561 ↗
50. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors10.1073/pnas.0915174107 ↗
51. Impaired HLA class i antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer10.1158/2159-8290.CD-17-0593 ↗
52. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
53. Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials10.1186/s12943-023-01800-3 ↗
54. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients10.1172/JCI80445 ↗
55. Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy10.1021/jacs.1c09753 ↗
56. Photothermal "nano-dot" reactivate "immune-hot" for tumor treatment via reprogramming cancer cells metabolism10.1016/j.biomaterials.2023.122089 ↗